- Home
- KRKR vs PHGE Comparison
KRKR vs PHGE Comparison
Compare KRKR & PHGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRKR
- PHGE
- Stock Information
- Founded
- KRKR 2010
- PHGE 2015
- Country
- KRKR China
- PHGE Israel
- Employees
- KRKR N/A
- PHGE N/A
- Industry
- KRKR Business Services
- PHGE Biotechnology: Pharmaceutical Preparations
- Sector
- KRKR Consumer Discretionary
- PHGE Health Care
- Exchange
- KRKR Nasdaq
- PHGE Nasdaq
- Market Cap
- KRKR 14.5M
- PHGE 12.6M
- IPO Year
- KRKR 2019
- PHGE N/A
- Fundamental
- Price
- KRKR $7.20
- PHGE $0.56
- Analyst Decision
- KRKR
- PHGE Strong Buy
- Analyst Count
- KRKR 0
- PHGE 1
- Target Price
- KRKR N/A
- PHGE $15.00
- AVG Volume (30 Days)
- KRKR 79.8K
- PHGE 292.1K
- Earning Date
- KRKR 09-26-2025
- PHGE 11-13-2025
- Dividend Yield
- KRKR N/A
- PHGE N/A
- EPS Growth
- KRKR N/A
- PHGE N/A
- EPS
- KRKR N/A
- PHGE N/A
- Revenue
- KRKR $30,966,526.00
- PHGE N/A
- Revenue This Year
- KRKR $182.55
- PHGE N/A
- Revenue Next Year
- KRKR N/A
- PHGE N/A
- P/E Ratio
- KRKR N/A
- PHGE N/A
- Revenue Growth
- KRKR N/A
- PHGE N/A
- 52 Week Low
- KRKR $2.76
- PHGE $0.34
- 52 Week High
- KRKR $21.36
- PHGE $1.16
- Technical
- Relative Strength Index (RSI)
- KRKR 51.29
- PHGE 58.26
- Support Level
- KRKR $6.90
- PHGE $0.47
- Resistance Level
- KRKR $7.57
- PHGE $0.54
- Average True Range (ATR)
- KRKR 0.59
- PHGE 0.03
- MACD
- KRKR -0.17
- PHGE 0.00
- Stochastic Oscillator
- KRKR 25.13
- PHGE 99.28
About KRKR 36Kr Holdings Inc.
36KR Holdings Inc is a holding company and conducts its business mainly through its subsidiaries, a VIE, and subsidiaries of the VIE. The Group is engaging in providing content and business services to new economy participants in the PRC. Its content production process includes content creation, content editing, screening and monitoring, and content distribution. The Group mainly generates revenues from providing online advertising services, enterprise value-added services, and subscription services. The Group's principal operations and geographic markets are substantially located in PRC.
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is engaged in developing both natural and engineered phage cocktails and personalized treatments designed to target and destroy harmful bacteria in chronic diseases, including cystic fibrosis and diabetic foot osteomyelitis. It discovers and validates proprietary bacterial targets and customizes phage compositions against these targets, and applies its BOLT (BacteriOphage Lead to Treatment) platform to customize phage compositions against these targets. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF. Its BX211 - Treatment of Diabetic Foot Osteomyelitis (DFO).